Evidence map›Paper›PMID 27467164›Full record

ArticlePloS one2016

High Resistance to Azithromycin in Clinical Samples from Patients with Sexually Transmitted Diseases in Guangxi Zhuang Autonomous Region, China.

Bangyong Zhu, Jin Bu, Wei Li, Jie Zhang, Geng Huang, Juan Cao, Zhongshu Tang, Quan Gan, Pingjiang Wei

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Bangyong ZhuCentral laboratory, Guangxi Institute of Dermatology, Nanning, Guangxi Zhuang Autonomous Region, China.
Jin BuEditorial Department of Journals of Nanjing Medical University, Nanjing Medical University, Nanjing, Jiangsu, China.ORCID http://orcid.org/0000-0001-8555-0922
Wei LiDepartment of Dermatology, Guangxi Institute of Dermatology, Nanning, Guangxi Zhuang Autonomous Region, China.
Jie ZhangDepartment of Dermatology, Guangxi Institute of Dermatology, Nanning, Guangxi Zhuang Autonomous Region, China.
Geng HuangDepartment of Dermatology, Guangxi Institute of Dermatology, Nanning, Guangxi Zhuang Autonomous Region, China.
Juan CaoDepartment of Dermatology, Guangxi Institute of Dermatology, Nanning, Guangxi Zhuang Autonomous Region, China.
Zhongshu TangDepartment of Dermatology, Guangxi Institute of Dermatology, Nanning, Guangxi Zhuang Autonomous Region, China.
Quan GanCentral laboratory, Guangxi Institute of Dermatology, Nanning, Guangxi Zhuang Autonomous Region, China.
Pingjiang WeiCentral laboratory, Guangxi Institute of Dermatology, Nanning, Guangxi Zhuang Autonomous Region, China.
Nanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Azithromycin is used as an alternative medicine in patients with syphilis who are intolerant to penicillin. Nevertheless, the report of treatment failure of azithromycin for patients with syphilis has raised concerns in China in the past years. In this study, 178 patients with early syphilis, who were treated in sexually transmitted infections clinics in four cities in Guangxi Zhuang Autonomous Region were enrolled to investigate the regional prevalence of Treponema pallidum strain resistant to azithromycin. Nested PCR was performed to amplify the 23S ribosomal RNA (23SrRNA) gene. The point mutation of A2058G in 23SrRNA, which confers Treponema pallidum resistance to azithromycin, was measured by endonuclease digestion of PCR amplification products using MboII. A2058G point mutation was detected in 91.0% (162/178; 95% CI, 86.8%, 95.2%) of the specimens, but no difference in prevalence of azithromycin resistance was found between the patients who had taken antibiotics before enrollment and the patients who had not (91.8% vs. 89.4%), nor between the patients with and without past sexually transmitted infections (87.1% vs. 93.1%). We concluded that azithromycin may not be suitable for syphilis as a treatment option in Guangxi Zhuang Autonomous Region because of the extremely high prevalence of resistance in the general syphilis population.

Indexed as

AdultAnti-Bacterial AgentsAzithromycinChinaDrug Resistance, BacterialFemaleHumansMaleMiddle AgedPoint MutationPolymerase Chain ReactionSyphilisTreponema pallidumAnti-Bacterial AgentsAzithromycin

Identifiers

PMID27467164
PMCPMC4965067
OpenAlexW2504370880

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.